Document is current
Any future updates will be listed below
-
Authors
Guerrero, Justin A. https://orcid.org/0000-0003-1537-4825
Klysz, Dorota D. https://orcid.org/0000-0002-6733-6110
Chen, Yiyun
Malipatlolla, Meena
Lone, Jameel
Fowler, Carley https://orcid.org/0000-0003-3003-0174
Stuani, Lucille https://orcid.org/0000-0001-6116-981X
May, Audre
Bashti, Malek https://orcid.org/0000-0003-0398-3367
Xu, Peng
Huang, Jing
Michael, Basil
Contrepois, Kévin
Dhingra, Shaurya https://orcid.org/0000-0002-5327-7535
Fisher, Chris
Svensson, Katrin J. https://orcid.org/0000-0001-5376-5128
Davis, Kara L. https://orcid.org/0000-0002-7182-2592
Kasowski, Maya
Feldman, Steven A. https://orcid.org/0000-0003-2098-3860
Sotillo, Elena https://orcid.org/0000-0002-3993-1932
Mackall, Crystal L. https://orcid.org/0000-0001-6323-4304
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01DK125260, P30DK116074)
U.S. Department of Health & Human Services | National Institutes of Health
Blavatnik Family Foundation.
- License Information
-
More Information
Article History
Received: 20 September 2023
Accepted: 18 September 2024
First Online: 6 October 2024
Competing interests
: C.L.M. is a cofounder of and holds equity in Link Cell Therapies, CARGO therapeutics and GBM NewCo. E.S holds equity in Lyell Immunopharma and consults for Lepton Pharmaceuticals and Galaria. S.A.F. serves on the Scientific Advisory Boards for Alaunos Therapeutics and Fresh Wind Biotech and has equity interest in both; S.A.F. receives research funding from CARGO and Tune Therapeutics. C.L.M. receives research funding from Lyell, Tune and consults for CARGO, Link, GBMNewCo, Immatics, and Ensoma. K.L.D is a St. Baldrick’s Foundation Scholar and acknowledges support from Hyundai Hope on Wheels and Oxnard Foundation (K.L.D.). K.C. is currently employed by AstraZeneca. The remaining authors declare no competing interests.
